Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.
Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.
A French study1 recently presented at the European Committee for Treatment and Research in Multiple Sclerosis investigated the impact of rituximab on regulatory T-cells (Treg), which play a role in immune modulation and have been identified as promoting oligodendrocyte differentiation and remyelination.
A total of 43 patients with MS, 19 with relapsing-remitting and 24 with progressive disease, received 1000 mg rituximab intravenously, followed by a maintenance dose of 1000 mg in 6 months.
Researchers recorded circulating lymphocyte kinetics (B CD19/B CD20/B CD27/T CD4/T CD8/Treg/NK cells) before the first infusion (M0) and 6 months later (M6). Secondary outcomes were the annualized relapse rate (ARR), expanded disability status scale (EDSS), and MRI activity.
Mean (SD) EDSS at baseline was 5.2 (1.4) and 5.3 (1.5) at 6 months, respectively. ARR significantly decreased at M6 from a mean 1.18 (1.2) to 0.18 (0.6) (P=.00094). MRI activity was reported in 11% of patients, compared with 56% at baseline. Levels of CD19+ and CD27+ memory B-cell lymphocytes were significantly depleted at M6 (both P <.0001). Although percentages of CD8+ lymphocytes remained unchanged, a significant increase in CD4+ lymphocyte levels was found at M6 [M0: 44.7% (10.8) to M6: 52.6% (8.8); P=.0008].
Among CD4+ T cells, activated Treg percentage remained unchanged. However, quiescent Treg significantly increased (M0: 1.56% [1.36] to M6: 2.3% [2.2]; P=.036). There was no observed change in natural killer and natural killer T-cell populations.
These results suggest that rituximab treatment is associated with an unexpected upregulation of circulating CD4+ lymphocytes and quiescent Treg levels, the latter of which the researchers hypothesize could reflect the reduced conversion of Treg into activated Treg in rituximab responders. However, future trials with a larger cohort and a longer follow-up are needed.
A second study2 presented at the same meeting compared rituximab with fingolimod, dimethyl fumarate, and natalizumab in patients with MS. Most had relapsing-remitting disease. Researchers found the odds of discontinuing treatment at 24 months or less was lower for patients taking rituximab versus fingolimod and dimethyl fumarate. The researchers said that rituximab demonstrated the lowest unadjusted disease activity outcomes of all the treatments, which are considered highly effective therapies.
The study included 182, 271, 342, and 451 patients who initiated rituximab, fingolimod, dimethyl fumarate, and natalizumab, respectively, between January 2010 and October 2013. The primary outcome was the probability of drug discontinuation by the end of year 2. The researchers controlled for age, disease duration, type of MS, gender, and enhancing lesion at baseline.
At 24 months, 46 (25.3%), 93 (34.3%), 161 (47.1%), and 147 (32.6%) patients discontinued rituximab, fingolimod, dimethyl fumarate, and natalizumab, respectively. Fingolimod versus rituximab had an adjusted odds ratio (aOR) of 1.96 (95% CI, 1.23-3.13; P=.005) of discontinuation by 24 months. Dimethyl fumarate versus rituximab had an aOR of 3.32 (95% CI, 2.15-5.13; P <.001). Natalizumab versus rituximab had an aOR of 1.50 (95% CI, 0.99-2.28; P =.109).
The leading cause of discontinuation of rituximab and natalizumab were issues involving insurance (9.9%), and being positive for John Cunningham Virus (12.6%), respectively.
Adverse events were the leading cause for discontinuation of fingolimod (17%) and dimethyl fumarate (24.0%). Fewer rituximab-treated patients (14.8%) experienced disease activity during follow-up compared with fingolimod (34.7%, P <.001), dimethyl fumarate (33.6%, P <.001), and natalizumab (22.2%, P =.037).
References
1. Maillart E, Ungureanu A, Derai D, et al. Impact of rituximab on Treg lymphocytes in MS patients. Presented at the European Committee for the Treatment and Research in Multiple Sclerosis annual meeting, October 10-12, 2018; Berlin, Germany. Abstract P554. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228398/elisabeth.maillart.impact.of.rituximab.on.treg.lymphocytes.in.ms.patients.html?f=media=3*search=rituximab*browseby=8.
2. Vollmer B, Nair K, Sillau S, Corboy J, Vollmer T, Alvarez E. Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Presented at the European Committee for the Treatment and Research in Multiple Sclerosis annual meeting, October 10-12, 2018; Berlin, Germany. Abstract P562. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228406/brandi.vollmer.comparison.of.rituximab.vs.fingolimod.dimethyl.fumarate.and.html?f=menu=14*media=3*speaker=546718*browseby=8.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.